The Hepatitis B Virus Polymerase Mutation rtV173L Is Selected during Lamivudine Therapy and Enhances Viral Replication In Vitro

William E. Delaney, Huiling Yang, Christopher E. Westland, Kalyan Das, Eddy Arnold, Craig S. Gibbs, Michael D. Miller, Shelly Xiong

Research output: Contribution to journalArticle

218 Citations (Scopus)

Abstract

Therapy of chronic hepatitis B virus (HBV) infection with the polymerase inhibitor lamivudine frequently is associated with the emergence of viral resistance. Genotypic changes in the YMDD motif (reverse transcriptase [rt] mutations rtM204V/I) conferred resistance to lamivudine as well as reducing the in vitro replication efficiency of HBV. A second mutation, rtL180M, was previously reported to partially restore replication fitness as well as to augment drug resistance in vitro. Here we report the functional characterization of a third polymerase mutation (rtV173L) associated with resistance to lamivudine and famciclovir. rtV173L was observed at baseline in 9 to 22% of patients who entered clinical trials of adefovir dipivoxil for the treatment of lamivudine-resistant HBV. In these patients, rtV173L was invariably found as a third mutation in conjunction with rtL180M and rtM204V. In vitro analyses indicated that rtV173L did not alter the sensitivity of wild-type or lamivudine-resistant HBV to lamivudine, penciclovir, or adefovir but instead enhanced viral replication efficiency. A molecular model of HBV polymerase indicated that residue rtV173 is located beneath the template strand of HBV nucleic acid near the active site of the reverse transcriptase. Substitution of leucine for valine at this residue may enhance polymerization either by repositioning the template strand of nucleic acid or by affecting other residues involved in the polymerization reaction. Together, these results suggest that rtV173L is a compensatory mutation that is selected in lamivudine-resistant patients due to an enhanced replication phenotype.

Original languageEnglish (US)
Pages (from-to)11833-11841
Number of pages9
JournalJournal of virology
Volume77
Issue number21
DOIs
StatePublished - Nov 1 2003

Fingerprint

Lamivudine
Hepatitis B virus
virus replication
mutation
therapeutics
Mutation
RNA-directed DNA polymerase
RNA-Directed DNA Polymerase
polymerization
nucleic acids
Polymerization
Nucleic Acids
Therapeutics
chronic hepatitis B
molecular models
drug resistance
Molecular Models
valine
active sites
Chronic Hepatitis B

All Science Journal Classification (ASJC) codes

  • Microbiology
  • Immunology
  • Insect Science
  • Virology

Cite this

Delaney, William E. ; Yang, Huiling ; Westland, Christopher E. ; Das, Kalyan ; Arnold, Eddy ; Gibbs, Craig S. ; Miller, Michael D. ; Xiong, Shelly. / The Hepatitis B Virus Polymerase Mutation rtV173L Is Selected during Lamivudine Therapy and Enhances Viral Replication In Vitro. In: Journal of virology. 2003 ; Vol. 77, No. 21. pp. 11833-11841.
@article{3d829a5b983442d78a51c09228d20015,
title = "The Hepatitis B Virus Polymerase Mutation rtV173L Is Selected during Lamivudine Therapy and Enhances Viral Replication In Vitro",
abstract = "Therapy of chronic hepatitis B virus (HBV) infection with the polymerase inhibitor lamivudine frequently is associated with the emergence of viral resistance. Genotypic changes in the YMDD motif (reverse transcriptase [rt] mutations rtM204V/I) conferred resistance to lamivudine as well as reducing the in vitro replication efficiency of HBV. A second mutation, rtL180M, was previously reported to partially restore replication fitness as well as to augment drug resistance in vitro. Here we report the functional characterization of a third polymerase mutation (rtV173L) associated with resistance to lamivudine and famciclovir. rtV173L was observed at baseline in 9 to 22{\%} of patients who entered clinical trials of adefovir dipivoxil for the treatment of lamivudine-resistant HBV. In these patients, rtV173L was invariably found as a third mutation in conjunction with rtL180M and rtM204V. In vitro analyses indicated that rtV173L did not alter the sensitivity of wild-type or lamivudine-resistant HBV to lamivudine, penciclovir, or adefovir but instead enhanced viral replication efficiency. A molecular model of HBV polymerase indicated that residue rtV173 is located beneath the template strand of HBV nucleic acid near the active site of the reverse transcriptase. Substitution of leucine for valine at this residue may enhance polymerization either by repositioning the template strand of nucleic acid or by affecting other residues involved in the polymerization reaction. Together, these results suggest that rtV173L is a compensatory mutation that is selected in lamivudine-resistant patients due to an enhanced replication phenotype.",
author = "Delaney, {William E.} and Huiling Yang and Westland, {Christopher E.} and Kalyan Das and Eddy Arnold and Gibbs, {Craig S.} and Miller, {Michael D.} and Shelly Xiong",
year = "2003",
month = "11",
day = "1",
doi = "10.1128/JVI.77.21.11833-11841.2003",
language = "English (US)",
volume = "77",
pages = "11833--11841",
journal = "Journal of Virology",
issn = "0022-538X",
publisher = "American Society for Microbiology",
number = "21",

}

The Hepatitis B Virus Polymerase Mutation rtV173L Is Selected during Lamivudine Therapy and Enhances Viral Replication In Vitro. / Delaney, William E.; Yang, Huiling; Westland, Christopher E.; Das, Kalyan; Arnold, Eddy; Gibbs, Craig S.; Miller, Michael D.; Xiong, Shelly.

In: Journal of virology, Vol. 77, No. 21, 01.11.2003, p. 11833-11841.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The Hepatitis B Virus Polymerase Mutation rtV173L Is Selected during Lamivudine Therapy and Enhances Viral Replication In Vitro

AU - Delaney, William E.

AU - Yang, Huiling

AU - Westland, Christopher E.

AU - Das, Kalyan

AU - Arnold, Eddy

AU - Gibbs, Craig S.

AU - Miller, Michael D.

AU - Xiong, Shelly

PY - 2003/11/1

Y1 - 2003/11/1

N2 - Therapy of chronic hepatitis B virus (HBV) infection with the polymerase inhibitor lamivudine frequently is associated with the emergence of viral resistance. Genotypic changes in the YMDD motif (reverse transcriptase [rt] mutations rtM204V/I) conferred resistance to lamivudine as well as reducing the in vitro replication efficiency of HBV. A second mutation, rtL180M, was previously reported to partially restore replication fitness as well as to augment drug resistance in vitro. Here we report the functional characterization of a third polymerase mutation (rtV173L) associated with resistance to lamivudine and famciclovir. rtV173L was observed at baseline in 9 to 22% of patients who entered clinical trials of adefovir dipivoxil for the treatment of lamivudine-resistant HBV. In these patients, rtV173L was invariably found as a third mutation in conjunction with rtL180M and rtM204V. In vitro analyses indicated that rtV173L did not alter the sensitivity of wild-type or lamivudine-resistant HBV to lamivudine, penciclovir, or adefovir but instead enhanced viral replication efficiency. A molecular model of HBV polymerase indicated that residue rtV173 is located beneath the template strand of HBV nucleic acid near the active site of the reverse transcriptase. Substitution of leucine for valine at this residue may enhance polymerization either by repositioning the template strand of nucleic acid or by affecting other residues involved in the polymerization reaction. Together, these results suggest that rtV173L is a compensatory mutation that is selected in lamivudine-resistant patients due to an enhanced replication phenotype.

AB - Therapy of chronic hepatitis B virus (HBV) infection with the polymerase inhibitor lamivudine frequently is associated with the emergence of viral resistance. Genotypic changes in the YMDD motif (reverse transcriptase [rt] mutations rtM204V/I) conferred resistance to lamivudine as well as reducing the in vitro replication efficiency of HBV. A second mutation, rtL180M, was previously reported to partially restore replication fitness as well as to augment drug resistance in vitro. Here we report the functional characterization of a third polymerase mutation (rtV173L) associated with resistance to lamivudine and famciclovir. rtV173L was observed at baseline in 9 to 22% of patients who entered clinical trials of adefovir dipivoxil for the treatment of lamivudine-resistant HBV. In these patients, rtV173L was invariably found as a third mutation in conjunction with rtL180M and rtM204V. In vitro analyses indicated that rtV173L did not alter the sensitivity of wild-type or lamivudine-resistant HBV to lamivudine, penciclovir, or adefovir but instead enhanced viral replication efficiency. A molecular model of HBV polymerase indicated that residue rtV173 is located beneath the template strand of HBV nucleic acid near the active site of the reverse transcriptase. Substitution of leucine for valine at this residue may enhance polymerization either by repositioning the template strand of nucleic acid or by affecting other residues involved in the polymerization reaction. Together, these results suggest that rtV173L is a compensatory mutation that is selected in lamivudine-resistant patients due to an enhanced replication phenotype.

UR - http://www.scopus.com/inward/record.url?scp=0142092372&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0142092372&partnerID=8YFLogxK

U2 - 10.1128/JVI.77.21.11833-11841.2003

DO - 10.1128/JVI.77.21.11833-11841.2003

M3 - Article

C2 - 14557667

AN - SCOPUS:0142092372

VL - 77

SP - 11833

EP - 11841

JO - Journal of Virology

JF - Journal of Virology

SN - 0022-538X

IS - 21

ER -